Canaccord Genuity launched coverage of Exagen (NASDAQ:XGN) with a “buy” rating and $25 price target. The stock closed at $16.69 on April 14. Analyst Max Masucci writes that Exagen provides a broad range of tests used to...
Analysts for BTIG, Canaccord Genuity and Alliance Global Partners had mixed reviews of preliminary fourth quarter results for T2 Biosystems (NASDAQ:TTOO),a leader in the rapid detection of sepsis-causing pathogens. Mark...
Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...
Canaccord Genuity raised its price target for Chembio Diagnostics (NASDAQ:CEMI) to $10 from $7, citing the launch of its 15-minute dual path platform (DPP) COVID-19 serology test in the U.S. The stock closed at $7.16 on...